quinacrine has been researched along with Lupus Erythematosus, Systemic in 116 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Many of these reviews, while generally excellent, have propagated some apparent misconceptions by disregarding or de-emphasizing data suggesting that irreversible retinal toxicity due to antimalarials can be easily avoided by judicious daily dosage and regular ophthalmologic follow-up." | 2.36 | Antimalarials and ophthalmologic safety. ( Olansky, AJ, 1982) |
| "Methods Mepacrine was added to 46 systemic lupus erythematosus patients unresponsive to treatment with the following drug combinations: hydroxychloroquine + prednisone + immunosuppressive drugs ( n = 24), hydroxychloroquine + prednisone ( n = 16), hydroxychloroquine + prednisone + retinoids ( n = 2), hydroxychloroquine alone ( n = 1), hydroxychloroquine + one immunosuppressive drug ( n = 1), hydroxychloroquine + prednisone + one immunosuppressive drug + belimumab ( n = 1) or hydroxychloroquine + prednisone + belimumab ( n = 1)." | 1.48 | Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. ( Agesta, N; Martinez-Zapico, A; Ortego-Centeno, N; Porta, S; Ríos, R; Ruiz-Irastorza, G; Ugarte, A, 2018) |
| "A total of 218 individuals with CLE or systemic lupus erythematosus and lupus nonspecific skin disease seen between January 5, 2007, and July 30, 2010." | 1.38 | Impact of smoking in cutaneous lupus erythematosus. ( Chang, AY; Feng, R; Foering, KP; Okawa, J; Piette, EW; Ten Have, TR; Werth, VP, 2012) |
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 102 (87.93) | 18.7374 |
| 1990's | 1 (0.86) | 18.2507 |
| 2000's | 6 (5.17) | 29.6817 |
| 2010's | 6 (5.17) | 24.3611 |
| 2020's | 1 (0.86) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, J | 1 |
| Vazquez, T | 1 |
| Chin, F | 1 |
| Keyes, E | 1 |
| Yan, D | 1 |
| Diaz, D | 1 |
| Grinnell, M | 1 |
| Sharma, M | 1 |
| Li, Y | 1 |
| Feng, R | 2 |
| Sprow, G | 1 |
| Dan, J | 1 |
| Werth, VP | 2 |
| Ugarte, A | 2 |
| Porta, S | 1 |
| Ríos, R | 1 |
| Martinez-Zapico, A | 1 |
| Ortego-Centeno, N | 1 |
| Agesta, N | 1 |
| Ruiz-Irastorza, G | 2 |
| Danza, A | 1 |
| McCune, WJ | 1 |
| Gonzalez-Rivera, T | 1 |
| Stannard, JN | 1 |
| Kahlenberg, JM | 1 |
| Cavazzana, I | 1 |
| Sala, R | 1 |
| Bazzani, C | 1 |
| Ceribelli, A | 1 |
| Zane, C | 1 |
| Cattaneo, R | 1 |
| Tincani, A | 1 |
| Calzavara-Pinton, PG | 1 |
| Franceschini, F | 1 |
| Berk, DR | 1 |
| Miller, A | 1 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
| Piette, EW | 1 |
| Foering, KP | 1 |
| Chang, AY | 1 |
| Okawa, J | 1 |
| Ten Have, TR | 1 |
| Toubi, E | 3 |
| Kessel, A | 3 |
| Rosner, I | 3 |
| Rozenbaum, M | 3 |
| Lorber, M | 1 |
| Paran, D | 2 |
| Sabo, E | 1 |
| Golan, TD | 2 |
| SOMMERVILLE, J | 1 |
| DEVINE, DC | 1 |
| PURSE, JC | 1 |
| CRAMER, JA | 1 |
| LEWIS, GM | 1 |
| SAWICKY, HH | 1 |
| KANOF, NB | 1 |
| SILVERBERG, MG | 1 |
| BRAITMAN, M | 1 |
| KALISH, B | 1 |
| WELLS, GC | 2 |
| COURVILLE, CJ | 1 |
| PERRY, ET | 1 |
| O'LEARY, PA | 3 |
| BRUNSTING, LA | 4 |
| KIERLAND, RR | 3 |
| BLACK, H | 1 |
| VAN DE WALLE, SM | 1 |
| KUYPERS, CA | 1 |
| ZAKON, SJ | 1 |
| KRAUS, Z | 1 |
| SOBKOVA, M | 1 |
| BOL'SHAKOVA, GM | 1 |
| HASERICK, JR | 2 |
| BURDICK, KH | 1 |
| BROOKINGS, D | 1 |
| KAMINSKY, A | 1 |
| KNALLINSKY, M | 1 |
| HARVEY, G | 1 |
| COCHRANE, T | 1 |
| MILLER, F | 1 |
| PAGE, F | 2 |
| CONEJO MIR, J | 1 |
| PARMER, LG | 1 |
| SAWITSKY, A | 1 |
| FARBER, EM | 1 |
| DRIVER, IE | 1 |
| ZELLER, F | 1 |
| COLE, HN | 2 |
| CHIVINGTON, PV | 1 |
| DRIVER, JR | 1 |
| SERRI, F | 1 |
| TINOZZI, CC | 1 |
| RHODES, BL | 1 |
| ALLENDE, MF | 1 |
| CAHN, MM | 2 |
| LEVY, EJ | 2 |
| SHAFFER, B | 2 |
| PETRANY, G | 1 |
| LEOVEY, A | 1 |
| CORDERO, AA | 2 |
| KENNEDY, CB | 1 |
| HENINGTON, VM | 1 |
| GARVIN, WH | 1 |
| BAHCALL, C | 1 |
| KOLLAR, K | 1 |
| HELANEN, S | 1 |
| MUSTAKALLIO, KK | 1 |
| ROGERS, J | 1 |
| FINN, OA | 1 |
| DUBOIS, EL | 3 |
| BUCHANAN, R | 1 |
| KING, H | 1 |
| HAMILTON, CM | 1 |
| EL-SHARKAWY, AG | 1 |
| MOHAREB, RW | 1 |
| MITZE, A | 1 |
| THIES, W | 2 |
| SYLVESTER, DG | 1 |
| BERESTON, ES | 1 |
| COHEN, MM | 1 |
| VILANOVA, X | 2 |
| ZAVARINI, G | 1 |
| DE JONGH, J | 1 |
| PATON, MD | 1 |
| RIDDELL, MJ | 1 |
| STRONG, JA | 1 |
| MAGNIN, PH | 1 |
| QUINONES, PA | 1 |
| RUIZ MARTIN, N | 1 |
| THIEL, E | 1 |
| RUST, S | 1 |
| KRAUSKOPF, J | 1 |
| CHRISTIANSEN, JV | 4 |
| NIELSEN, JP | 3 |
| PUCHSTEIN, G | 1 |
| MARCHIONINI, A | 1 |
| CONNER, SK | 1 |
| REIN, CR | 1 |
| FLEISCHMAJER, R | 1 |
| GEORGIEV, G | 1 |
| BAZHDEKOV, B | 1 |
| TYE, MJ | 2 |
| ANSELL, HB | 2 |
| WOLF, M | 1 |
| APPEL, B | 2 |
| SCHIFF, B | 1 |
| WISKEMANN, A | 1 |
| KOCH, H | 1 |
| VIDMAR-CVJETANOVIC, B | 1 |
| ROBINSON, RC | 1 |
| SMITH, GC | 1 |
| WHITE, H | 1 |
| SHEARD, C | 1 |
| MARCIANO, MR | 1 |
| BEZZABOTNOV, AS | 1 |
| LEBEDEV, BM | 1 |
| DROJECKI, A | 1 |
| ZIELINSKI, J | 1 |
| CZERNIELEWSKI, A | 1 |
| FREDRIKSSON, T | 1 |
| LODIN, A | 1 |
| ROSENGREN, S | 1 |
| WINKELMANN, RK | 1 |
| MERWIN, CF | 1 |
| TUFFANELLI, D | 1 |
| ABRAHAM, RK | 1 |
| DUBOIS, EI | 1 |
| BORC, K | 1 |
| RAAB, W | 1 |
| RAY, RN | 1 |
| CHATTERJEA, JB | 1 |
| FULTON, WH | 1 |
| DYKEN, PR | 1 |
| RUTLEDGE, WU | 1 |
| BETTLEY, FR | 1 |
| HUTSEBAUT, A | 1 |
| DAINOW, I | 1 |
| OTTOLENGHI-LODIGIANI, F | 1 |
| LEHMANN, F | 1 |
| STOUGHTON, RB | 1 |
| FAST, K | 1 |
| WESTERBERG, P | 1 |
| OLSSON, IK | 1 |
| BRANDAO, N | 1 |
| DA FONSECA, A | 1 |
| Yebra-Bango, M | 1 |
| Tutor-Ureta, P | 1 |
| Shoenfeld, Y | 1 |
| Lanham, JG | 1 |
| Hughes, GR | 1 |
| Olansky, AJ | 1 |
| Wallace, DJ | 3 |
| Leigh, IM | 1 |
| Kennedy, CT | 1 |
| Ramsey, JD | 1 |
| Henderson, WJ | 1 |
| Clark, SK | 1 |
| Huriez, C | 1 |
| Desmons, F | 1 |
| Gautier, G | 1 |
| Freeman, RG | 1 |
| Knox, JM | 1 |
| Owens, DW | 1 |
| Carr, RE | 1 |
| Henkind, P | 1 |
| Rothfield, N | 1 |
| Siegel, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease[NCT00183092] | Phase 2 | 69 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition." (NCT00183092)
Timeframe: Baseline, 2 months
| Intervention | number of words generated (Mean) |
|---|---|
| Placebo | -2.4 |
| Quinacrine | -2.2 |
ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance. (NCT00183092)
Timeframe: Baseline, 2 months
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 13.0 |
| Quinacrine | 12.6 |
An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone. (NCT00183092)
Timeframe: baseline, 2 months
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -23.2 |
| Quinacrine | -13.2 |
Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone. (NCT00183092)
Timeframe: Baseline, 2 months
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.2 |
| Quinacrine | 0.3 |
The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing. (NCT00183092)
Timeframe: Baseline to Month-2
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -6.9 |
| Quinacrine | -3.9 |
"The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone." (NCT00183092)
Timeframe: Baseline, 2 months
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.8 |
| Quinacrine | 0.3 |
Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition. (NCT00183092)
Timeframe: Baseline, 2 months
| Intervention | number of words generated (Mean) |
|---|---|
| Placebo | -3.2 |
| Quinacrine | -2.2 |
Participants alive after 2 months on study treatment (NCT00183092)
Timeframe: Randomization to Month-2
| Intervention | participants (Number) |
|---|---|
| Placebo | 19 |
| Quinacrine | 13 |
8 reviews available for quinacrine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions.
Topics: Antimalarials; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythema | 2018 |
Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2016 |
[ANTIMALARIALS IN THE TREATMENT OF SKIN DISEASES].
Topics: Adrenal Cortex Hormones; Antimalarials; Chloroquine; Dermatology; Humans; Lupus Erythematosus, Disco | 1963 |
Antimalarial therapy in SLE.
Topics: Antimalarials; Binding Sites; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Femal | 1982 |
Antimalarials and ophthalmologic safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, | 1982 |
Antimalarial agents and lupus.
Topics: Antibodies, Antiphospholipid; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Kidney | 1994 |
Antimalarials in the management of discoid and systemic lupus erythematosus.
Topics: Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Lupus Erythematosus, | 1978 |
The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination.
Topics: Chemical Phenomena; Chemistry; Female; Humans; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy C | 1989 |
3 trials available for quinacrine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Antimalarials; Drug Therapy, Combinati | 2003 |
The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Topics: Adult; Antibodies, Anticardiolipin; Antirheumatic Agents; Azathioprine; B-Cell Activating Factor; Ca | 2006 |
The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients.
Topics: Adult; Antimalarials; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; H | 2000 |
105 other studies available for quinacrine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus In Vivo Stratified by Patient Response to Antimalarials.
Topics: Antimalarials; Granzymes; Humans; Hydroxychloroquine; Immunosuppressive Agents; Interferon Regulator | 2022 |
Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Topics: Adult; Antimalarials; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunosuppressi | 2018 |
Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?
Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eye Diseases; Follow-Up | 2015 |
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Topics: Adult; Antimalarials; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2009 |
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |
Impact of smoking in cutaneous lupus erythematosus.
Topics: Adult; Antimalarials; Cohort Studies; Comorbidity; Cross-Sectional Studies; Drug Therapy, Combinatio | 2012 |
Lupus erythematosus treated with mepacrine.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1952 |
Atabrine in the treatment of discoid lupus erythematosus.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1952 |
Therapeutic assays of the Skin and Cancer Unit of the New York University Hospital. Assay VII-Quinacrine hydrochloride (atabrine hydrochloride) for chronic discoid lupus erythematosus.
Topics: Hospitals, University; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Neoplasms; New Y | 1952 |
Treatment of chronic discoid lupus erythematosus with atabrine.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1952 |
Quinacrine (atabrine) in treatment of lupus erythematosus.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Quinacrine (atabrine) hydrochloride in treatment of discoid lupus erythematosus.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine; Salts | 1953 |
The treatment of lupus erythematosus with mepacrine and para-aminobenzoic acid.
Topics: 4-Aminobenzoic Acid; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Chronic discoid lupus erythematosis treated with quinacrine hydrochloride (atabrine dihydrochloride).
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Atabrine therapy of lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Atabrine therapy of disseminated subacute lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Chronic discoid lupus erythematosus treated with quinacrine hydrochloride (atabrine dihydrochloride).
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Atabrine in the treatment of lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Combined acrichine and nicotinic acid therapy of lupus erythematosus].
Topics: Isomerism; Lupus Erythematosus, Systemic; Niacin; Nicotinic Acids; Quinacrine | 1953 |
Systemic lupus erythematosus: failure of quinacrine to maintain cortisone- and corticotropin-induced remission.
Topics: Adrenocorticotropic Hormone; Cortisone; Lupus Erythematosus, Systemic; Maintenance; Quinacrine; Remi | 1953 |
Lupus erythematosus treated with quinacrine hydrochloride [atabrine dihydrochloride].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Atabrine in therapy of lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
The treatment of lupus erythematosus with mepacrine (Atabrine).
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Atabrine therapy in discoid lupus erythematosus.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Mepacrine and lupus erythematosus.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Clinical considerations on the treatment of lupus erythematosus with atabrine].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Fatal aplastic anemia following quinacrine therapy in chronic discoid lupus erythematosus.
Topics: Anemia; Anemia, Aplastic; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Atabrine and chloroquine in the treatment of chronic discoid lupus erythematosus.
Topics: Chloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Quinacrine hydrochloride (atabrine) in the treatment of lupus erythematosus.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Treatment of chronic lupus erythematosus with atebrin].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Treatment of chronic discoid lupus erythematosus with quinacrine.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Quinacrine hydrochloride in the treatment of lupus erythematosus.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Atebrin in the treatment of lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Treatment of chronic discoid lupus erythematosus with quinacrine.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
The use of chloroquine diphosphate (aralen) and quinacrine (atabrine) hydrochloride in the prevention of polymorphorus light eruptions.
Topics: Biomedical Research; Chloroquine; Light; Lupus Erythematosus, Systemic; Quinacrine; Sunlight | 1954 |
[Significance of lupus erythematosus for internal medicine and its therapy with atebrin].
Topics: Internal Medicine; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
[Quinacrine hydrochlorate and vitamin B12 in the treatment of chronic lupus erythematosus].
Topics: Corrinoids; Hematinics; Lupus Erythematosus, Systemic; Quinacrine; Vitamin B 12 | 1953 |
Treatment of chronic discoid lupus erythematosus with atabrine.
Topics: Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
[Soviet achievements in chemotherapy of lupus erythematosus].
Topics: Achievement; Lupus Erythematosus, Systemic; Quinacrine | 1953 |
Treatment of chronic discoid lupus erythematosus with atabrine.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
Distribution of quinacrine (atabrine, mepacrine) in human tissues as visualized by fluorescent microscopy; considerations on the mode of action of quinacrine in lupus erythematosus.
Topics: Lupus Erythematosus, Systemic; Microscopy; Quinacrine | 1954 |
Synthetic antimalarial drugs in chronic discoid lupus erythematosus and light eruptions.
Topics: Antimalarials; Chloroquine; Light; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quin | 1954 |
Quinacrine (atabrine) in treatment of systemic and discoid lupus erythematosus.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
Quinacrine in discoid lupus erythematosus; the present day status.
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
Mepacrine atabrine in treatment of lupus erythematosus.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1954 |
Report on 11 cases of lupus erythematosus; treated with mepacrine at the Cairo Skin and V.D. Hospital.
Topics: Hospitals; Lupus Erythematosus, Systemic; Quinacrine; Skin | 1954 |
[Clinica note on the treatment of lupus erythematosus with atabrine].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1954 |
[Erythematodes chronicus disseminatus with bone and joint participation].
Topics: Bone and Bones; Humans; Joints; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
[Clinical experience in the treatment of chronic lupus erythematosus with atebrin].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1954 |
Systemic lupus erythematosus treated with ACTH and mepacrine.
Topics: Adrenocorticotropic Hormone; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
Greenish fluorescence of scalp hairs from quinacrine hydrochloride administration.
Topics: Fluorescence; Hair; Lupus Erythematosus, Systemic; Quinacrine; Scalp | 1954 |
[Atebrine and chloroquine/resochin therapy of lupus erythematous and dermatoses due to photosensitivity].
Topics: Chloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine; Skin Diseases | 1954 |
[Chronic lupus erythematosus and atabrine; case report with preventive note on the use of atabrine in pemphigus vulgaris].
Topics: Lupus Erythematosus, Systemic; Pemphigus; Quinacrine | 1954 |
[A case of subacute lupus erythematosus].
Topics: Adrenocorticotropic Hormone; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
Aplastic anaemia following mepacrine treatment of lupus erythematosus.
Topics: Anemia; Anemia, Aplastic; Lupus Erythematosus, Systemic; Quinacrine | 1955 |
[Quinacrine therapy of lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1954 |
[Toxic psychoses in atabrine treatment of lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders; | 1955 |
[Atabrine treatment of chronic lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1955 |
[Electrophoretic studies on atabrine therapy of chronic discoid lupus erythematosus].
Topics: Electrophoresis; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1955 |
[Pathogenesis and therapy of lupus erythematosus].
Topics: Central Nervous System; Lupus Erythematosus, Systemic; Quinacrine | 1955 |
Treatment of lupus erythematosus with mepacrine; results and relapses during a long observation.
Topics: Chronic Disease; Lupus Erythematosus, Systemic; Quinacrine; Recurrence | 1956 |
[Psychosis caused by atebrin therapy in lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders; | 1956 |
[Lupus erythematosus, etiology, pathogenesis and therapy].
Topics: Chloroquine; Lupus Erythematosus, Systemic; Quinacrine | 1956 |
[Mepacrine therapy of lupus erythematosus; results and review of recurrent cases over a long period of observation].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1956 |
[Mepacrine therapy of lupus erythematosus; results and review of recurrent cases over a long period of observation].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1956 |
[Mepacrine therapy of lupus erythematosus; results and review of recurrent cases over a long period of observation].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1956 |
[Mepacrine therapy of lupus erythematosus; results and review of recurrent cases over a long period of observation].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1956 |
Systemic lupus erythematosus; a report on twelve cases treated with quinacrine (atabrine) and chloroquine (aralen).
Topics: Chloroquine; Lupus Erythematosus, Systemic; Quinacrine | 1957 |
Treatment of lupus erythematosus with chloroquine; therapeutic results and a comparison of the value of chloroquine and mepacrine.
Topics: Chloroquine; Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1957 |
The treatment of lupus erythematosus and lymphocytic infiltration of the skin with A.P.A. 5533.
Topics: Chloroquine; Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine; Skin; | 1957 |
[Treatment of lupus erythematosus by local infiltrations of atabrine].
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1957 |
Treatment of chronic lupus erythematosus: effectiveness of plaquenil and APA (Aralen 65 mg., plaquenil 50 mg., Atabrine 25 mg.) as compared with Aralen, with observations on side-reactions and toxicity; report and presentation of unusual cases.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythema | 1958 |
[Experimental & clinical studies on the mechanism of action of atabrine & resochin in chronic lupus erythematosus].
Topics: Biomedical Research; Chloroquine; Lupus Erythematosus, Systemic; Quinacrine | 1958 |
[Atabrine and resohine therapy of lupus erythematosus].
Topics: Chloroquine; Lupus Erythematosus, Systemic; Quinacrine | 1957 |
Triquin in the treatment of discoid lupus erythematosus and light sensitive eruptions.
Topics: Chloroquine; Exanthema; Humans; Light; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; | 1958 |
Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1959 |
The use of triquin in the treatment of discoid lupus erythematosus and some other skin conditions.
Topics: Chloroquine; Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine; Skin D | 1959 |
[Treatment of patients with discoid forms of lupus erythematosus by applications of 10 per cent achrichine plaster].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1959 |
[Mental complications during therapy of lupus erythematosus with atabrine].
Topics: Lupus Erythematosus, Systemic; Mental Disorders; Quinacrine | 1960 |
[Immediate and remote results in the treatment of chronic lupus erythematosus with atabrine].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1961 |
[Treatment of discoid lupus erythematosus, polymorphous photodermatosis and rosacea with Triquin--a combination of 3 anti-malarials].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythema | 1962 |
Antimalarial therapy of lupus erythematosus.
Topics: Antimalarials; Lupus Erythematosus, Systemic; Quinacrine | 1961 |
PIGMENTATION FROM ANTIMALARIAL THERAPY. ITS POSSIBLE RELATIONSHIP TO THE OCULAR LESIONS.
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Cornea; Eye; Eye Manifestations; Histo | 1963 |
LUPUS ERYTHEMATOSUS--A CLINICAL QUIZ. A SERIES OF DIAGNOSTIC AND THERAPEUTIC PROBLEMS.
Topics: Chloroquine; Diagnosis; Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacr | 1963 |
POLYMORPHOUS LIGHT ERUPTION. A TEN-YEAR FOLLOW-UP AND EVALUATION.
Topics: Chloroquine; Dermatitis, Phototoxic; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus Erythemato | 1963 |
[CHRONIC DISCOID ERYTHEMATOSUS (REPORT ON 69 CASES OVER A PERIOD OF 6 YEARS FROM THE VIEWPOINT OF OPTIMUM THERAPY)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythema | 1963 |
SOME OBSERVATIONS ON L. E. PHENOMENON.
Topics: Adsorption; Anticoagulants; Chlorambucil; Citrates; Dexamethasone; Edetic Acid; Erythrocytes; Humans | 1963 |
NEUROLOGICAL SYNDROMES OF SYSTEMIC LUPUS ERYTHEMATOSUS.
Topics: Adolescent; Anticonvulsants; Autoimmune Diseases; Blood Proteins; Cerebral Cortex; Cerebrospinal Flu | 1964 |
WHAT'S NEW AND WHAT'S TRUE OF WHAT'S NEW IN DERMATOLOGY.
Topics: Amodiaquine; Dermatology; Humans; Hydroxychloroquine; Keratoacanthoma; Lupus Erythematosus, Discoid; | 1964 |
CHILBLAIN LUPUS ERYTHEMATOSUS.
Topics: Chilblains; Chloroquine; Fluocinolone Acetonide; Frostbite; Humans; Hydroxychloroquine; Hypothyroidi | 1964 |
Effect of quinacrine (atabrine) upon lupus erythematosus phenomenon.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1955 |
[Iontophoresis with atebrin in local therapy of erythematodes].
Topics: Ion Exchange; Iontophoresis; Lupus Erythematosus, Systemic; Quinacrine | 1954 |
[Five cases of chronic lupus erythematosus treated with atebrin].
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1954 |
[Atebrine and lupus erythematosus; normalizing effects of this drug on the porphyrine level].
Topics: Lupus Erythematosus, Systemic; Porphyrins; Quinacrine | 1955 |
[Treatment of chronic lupus erythematosus, local intradermal infiltration with an acridine preparation].
Topics: Acridines; Lupus Erythematosus, Systemic; Quinacrine | 1955 |
[Atebrin psychosis in the treatment of chronic lupus erythematosus].
Topics: Lupus Erythematosus, Systemic; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders; | 1955 |
Treatment of chronic lupus erythematosus with atabrine and chloroquine.
Topics: Chloroquine; Lupus Erythematosus, Systemic; Quinacrine | 1955 |
[Mepacrine in therapy of chronic discoid lupus erythematosus].
Topics: Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Quinacrine | 1955 |
Results of atabrine treatment of lupus erythematosus.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1955 |
[Treatment of chronic lupus erythematosus with synthetic antimalarials: quinacrine and chloroquine].
Topics: Antimalarials; Chloroquine; Humans; Lupus Erythematosus, Systemic; Quinacrine | 1955 |
Treatment of lupus erythematosus with mepacrine.
Topics: Lupus Erythematosus, Systemic; Quinacrine | 1951 |
[Systemic lupus erythematosus therapy. Antimalarials in inflammatory diseases].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Quinacrine | 2004 |
Is there a role for quinacrine (Atabrine) in the new millennium?
Topics: Antimalarials; Clinical Trials as Topic; Humans; Lupus Erythematosus, Systemic; Malaria; Quinacrine | 2000 |
Mepacrine pigmentation in systemic lupus erythematosus. New data from an ultrastructural, biochemical and analytical electron microscopic investigation.
Topics: Adolescent; Cytoplasmic Granules; Female; Humans; Iron; Lupus Erythematosus, Systemic; Microscopy, E | 1979 |
Cutaneous lupus erythematosus. Recognition of its many forms.
Topics: Adrenal Cortex Hormones; Adult; Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxychloroq | 1986 |
[Complications with synthetic antimalarials].
Topics: Antimalarials; Asthenia; Central Nervous System Diseases; Chloroquine; Drug Eruptions; Eczema; Eye D | 1969 |
Cutaneous lesions of lupus erythematosus induced by monochromatic light.
Topics: Acanthosis Nigricans; Edema; Erythema; Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Sy | 1969 |
Ocular toxicity of antimalarial drugs. Long-term follow-up.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Electrooculography; Electror | 1968 |